What is clear cell ovarian carcinoma?
Clear cell ovarian carcinoma is a distinct type of epithelial ovarian cancer. It is named after the pale, “clear” look of its cells under the microscope, which comes from stored sugar (glycogen).
It makes up about 5-10% of ovarian cancers in Europe and North America, but up to 20-25% in Japan and other parts of East Asia.
Clear cell carcinoma is closely linked with endometriosis, a common condition in which tissue similar to the womb lining grows outside the womb. Many tumours develop in an endometriosis cyst of the ovary (an endometrioma, or “chocolate cyst”).
Compared with the commonest ovarian cancer, high-grade serous carcinoma, it is more often found early, while it is still confined to the ovary. Early-stage disease has a good outlook after surgery.
When it has spread, however, clear cell carcinoma responds poorly to standard chemotherapy. It also carries a higher risk of blood clots. Research into new treatments, such as immunotherapy and drugs aimed at its gene changes, is active.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Epithelial ovarian cancer, clear cell type |
| How common | About 5-10% of ovarian carcinomas in Western countries; up to 20-25% in Japan |
| Typical age | Median about 50-55; younger than for serous cancer |
| Main risk factor | Endometriosis |
| Stage at diagnosis | About half or more are stage I-II |
| Key gene changes | ARID1A loss in about half; PIK3CA mutations in about 40-50% |
| Special features | High risk of blood clots; occasionally high blood calcium |
| Main treatments | Surgery with full staging; carboplatin and paclitaxel; trials of immunotherapy and targeted drugs |
| Outlook | Stage I: about 85-90% alive at 5 years; stage III-IV: about 20-30% |
2. How it differs from other ovarian cancers
| Feature | Clear cell | High-grade serous | Endometrioid |
|---|---|---|---|
| Link with endometriosis | Strong | Weak | Strong |
| Usual stage at diagnosis | Often early | Usually advanced | Often early |
| Response to platinum chemotherapy | Poor in advanced disease | Usually good at first | Usually good |
| Key genes | ARID1A, PIK3CA | TP53, BRCA1/2 | ARID1A, CTNNB1, PTEN |
| PARP inhibitors | Little benefit | Important treatment | Selected cases |
| CA125 | Often only mildly raised | Usually very high | Variable |
3. Causes and risk factors
| Factor | Notes |
|---|---|
| Endometriosis | Raises the risk of clear cell carcinoma about three-fold; still, very few women with endometriosis develop it |
| East Asian ancestry | Higher rates in Japan and other parts of Asia |
| Lynch syndrome | An inherited condition with faulty mismatch repair genes; linked to clear cell and endometrioid ovarian cancer |
| Never having children | Associated with higher risk of ovarian cancer generally |
| Gene changes in the tumour | ARID1A and PIK3CA changes, often already found in the nearby endometriosis |
| Protective factors | Tubal ligation and hysterectomy are linked to a lower risk of endometriosis-related ovarian cancers |
Endometriosis affects about 1 in 10 women of reproductive age, so the absolute risk of clear cell carcinoma remains small. Women with endometriosis do not need routine cancer screening, but endometriosis cysts that grow, develop solid areas or appear after the menopause should be checked with a specialist scan.
4. How does it look?
4.1 Inside the body and at surgery
| Feature | What it looks like |
|---|---|
| Size | Often a large mass, commonly 10-15 cm |
| Side | Usually one ovary |
| Inside | A cyst with one or more solid, fleshy nodules growing from the wall |
| Fluid | Often dark brown “chocolate” fluid when it arises in an endometriosis cyst |
| Surrounding tissue | Endometriosis on the pelvic lining, often with scarring and adhesions |
4.2 On scans
| Test | Typical findings |
|---|---|
| Pelvic ultrasound | A cyst with solid nodules that have a blood supply on Doppler |
| MRI | A bright cyst on T1 images (from old blood) with enhancing solid nodules |
| CT | Shows the extent of the tumour and spread, and can find blood clots |
4.3 Under the microscope
| Feature | What the pathologist sees |
|---|---|
| Cells | Clear or pink cells; “hobnail” cells with nuclei bulging into spaces |
| Patterns | Tubules, cysts, papillae and solid sheets, often mixed |
| Stains | Napsin A and HNF1-beta positive; usually oestrogen receptor and WT1 negative |
| Mismatch repair proteins | Tested to look for Lynch syndrome |
| ARID1A | Loss of the protein in about half of tumours |
5. Symptoms
5.1 Common symptoms
| Symptom | Notes |
|---|---|
| Pelvic or lower tummy pain | Often the first symptom |
| A lump or swelling in the tummy | From a large ovarian mass |
| Bloating | Persistent rather than coming and going |
| Feeling full quickly | Pressure on the stomach |
| Changes in bladder or bowel habits | Pressure from the mass |
| Symptoms of endometriosis | Painful periods, pain during sex, long-standing pelvic pain |
5.2 Warning signs of complications
| Symptom | Possible cause |
|---|---|
| Painful, swollen leg | Deep vein thrombosis (blood clot) |
| Sudden breathlessness or chest pain | Pulmonary embolism, an emergency |
| Thirst, confusion, constipation | High blood calcium caused by the tumour |
| Sudden severe pain | Twisting or rupture of the cyst |
5.3 When to see a doctor
See a doctor if you have bloating, pelvic pain, a swollen tummy or early fullness on most days for three weeks or more. Women with known endometriosis should report a change in their usual symptoms or a cyst that grows. Get emergency help for sudden breathlessness or chest pain.
6. Diagnosis
| Test | Why it is done |
|---|---|
| Pelvic examination | Feels for a mass |
| Transvaginal ultrasound | The first imaging test; describes solid parts and blood flow |
| CA125 and other markers | CA125 is often only mildly raised in clear cell carcinoma |
| MRI | Helps tell an endometriosis cyst from a cancer |
| CT of chest, abdomen and pelvis | Checks for spread and for blood clots |
| Surgery and pathology | Usually provides the final diagnosis |
| Germline genetic testing | Recommended for all women with epithelial ovarian cancer; includes Lynch syndrome genes |
Staging
The FIGO staging system is used: stage I is confined to the ovaries, stage II spreads within the pelvis, stage III to the abdominal lining or lymph nodes, and stage IV to distant organs.
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Endometrioma (“chocolate cyst”) | A benign endometriosis cyst with dark fluid but no solid, enhancing nodules |
| Endometrioid ovarian carcinoma | Also linked with endometriosis; different cells and usually ER positive |
| High-grade serous carcinoma with clear cells | Has TP53 changes and WT1 staining |
| Yolk sac tumour | A germ cell tumour of young women; raises AFP |
| Metastatic clear cell kidney cancer | Spread from the kidney; usually CD10 and RCC marker positive, and kidney scans show the primary tumour |
7. Treatment
Treatment is planned by a gynaecological oncology team at a specialist centre. Careful surgical staging is especially important, because finding the cancer at stage I can spare some women more intensive treatment.
7.1 Surgery
| Procedure | Notes |
|---|---|
| Hysterectomy and removal of both ovaries and tubes | Standard surgery |
| Full staging | Omentectomy, peritoneal biopsies and washings, and lymph node assessment for apparently early disease |
| Fertility-sparing surgery | Only for carefully selected young women with stage IA disease, after specialist discussion |
| Debulking surgery | For advanced disease, aiming to remove all visible tumour |
7.2 Chemotherapy and other drugs
Chemotherapy for clear cell carcinoma uses the same drugs as for other ovarian cancers, mainly carboplatin and paclitaxel, usually given every three weeks for six cycles. Research has not yet found a regimen that works better for this type.
| Situation | Approach |
|---|---|
| Stage IA, fully staged | Chemotherapy is discussed; some women may be safely observed |
| Stage IB-IC and II | Carboplatin and paclitaxel is usually recommended |
| Stage III-IV | Surgery plus carboplatin and paclitaxel, often with bevacizumab |
| Recurrence | Other chemotherapy; immunotherapy or targeted drugs in trials; surgery for selected recurrences |
| Mismatch repair-deficient tumours | Immune checkpoint drugs may work well |
7.3 Prevention of blood clots
Blood clots in the legs or lungs affect a notable proportion of women with clear cell carcinoma, more than with other ovarian cancers. They can occur before diagnosis, around surgery or during chemotherapy.
Because the risk of clots is high, doctors give blood-thinning injections around surgery and sometimes during chemotherapy.
8. Side effects of treatment
| Treatment | Possible effects | What helps |
|---|---|---|
| Surgery | Pain, wound problems, blood clots, early menopause | Pain relief, early walking, blood thinners, menopause advice |
| Carboplatin | Low blood counts, tiredness, nausea | Blood tests, anti-sickness medicines |
| Paclitaxel | Hair loss, numbness in hands and feet, joint aches | Cooling caps in some centres, dose changes |
| Bevacizumab | High blood pressure, protein in urine, wound healing problems, rarely bowel perforation | Monitoring blood pressure and urine |
9. Outlook
| Stage | Approximate 5-year survival |
|---|---|
| Stage I | About 85-90% |
| Stage II | About 60-70% |
| Stage III | About 20-35% |
| Stage IV | Under 20% |
Clear cell carcinoma often does better than serous cancer at stage I, but worse when it has spread, because chemotherapy works less well.
Within stage I, the outlook is best for stage IA and IC1 (tumour confined to the ovary, or rupture during surgery). It is less favourable when the cyst ruptured before surgery, cancer cells are found on the ovarian surface or in abdominal washings (IC2 and IC3).
Survival figures come from women treated years ago and may not reflect newer treatments. Your team can explain what the numbers mean for you.
10. Follow-up
| Time after treatment | Typical follow-up |
|---|---|
| Years 1-2 | Every 3-4 months: symptoms, examination, CA125 if it was raised, scans if needed |
| Years 3-5 | Every 6 months |
| After 5 years | Yearly or as advised |
Women who have had surgery that causes early menopause should discuss bone health and hormone therapy. Hormone replacement is often possible after clear cell carcinoma, but the decision is individual and should be made with the specialist team.
Report new pain, bloating, leg swelling or breathlessness promptly. Gentle exercise, a healthy diet and support from a specialist nurse can help recovery. If Lynch syndrome is found, relatives can be tested, and carriers are offered bowel screening.
11. Research directions
| Approach | Why it is being studied |
|---|---|
| Immune checkpoint drugs | Some clear cell cancers respond to drugs such as nivolumab or pembrolizumab, sometimes with other drugs |
| ARID1A-targeted treatments | Loss of ARID1A may make cells sensitive to ATR or EZH2 inhibitors |
| PI3K pathway drugs | Target PIK3CA mutations |
| Anti-angiogenic drugs | Block blood vessel growth in the tumour |
12. Frequently asked questions
| Question | Answer |
|---|---|
| Does endometriosis mean I will get this cancer? | No. Fewer than 1 in 100 women with endometriosis develop ovarian cancer |
| Is it inherited? | Usually not, but some cases are linked to Lynch syndrome; genetic testing is offered |
| Why is my CA125 not very high? | Clear cell carcinoma often raises CA125 less than serous cancer does |
| Will PARP inhibitors help me? | They are less useful than in serous cancer, unless a BRCA mutation is present |
| Why do I need blood thinners? | Clear cell carcinoma raises the risk of dangerous blood clots |
13. Questions to ask your care team
- What stage is my cancer, and were the lymph nodes checked?
- Do I need chemotherapy after surgery?
- Has my tumour been tested for mismatch repair deficiency, and should I have genetic testing?
- What is my risk of blood clots, and do I need blood thinners?
- Are there clinical trials for clear cell carcinoma I could join?
- Can I take hormone replacement therapy?
Resources
- WHO Classification of Tumours Editorial Board (2020) Female Genital Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
- Sugiyama, T. et al. (2000) ‘Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy’, Cancer, 88(11), pp. 2584-2589.
- Wiegand, K.C. et al. (2010) ‘ARID1A mutations in endometriosis-associated ovarian carcinomas’, New England Journal of Medicine, 363(16), pp. 1532-1543.
- Pearce, C.L. et al. (2012) ‘Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies’, The Lancet Oncology, 13(4), pp. 385-394.
- Okamoto, A. et al. (2014) ‘Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary’, International Journal of Gynecological Cancer, 24(9 Suppl 3), pp. S20-S25.
- Iida, Y. et al. (2021) ‘Clear cell carcinoma of the ovary: a clinical and molecular perspective’, International Journal of Gynecological Cancer, 31(4), pp. 605-616.
- Gonzalez-Martin, A. et al. (2023) ‘Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up’, Annals of Oncology, 34(10), pp. 833-848.
- National Cancer Institute (2026) Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.